NGNE NASDAQ
Neurogene Inc.
1W: -2.6%
1M: -16.9%
3M: -29.1%
YTD: +16.8%
1Y: -18.0%
3Y: +76.7%
5Y: -82.8%
$26.99
+3.45 (+14.66%)
After Hours: $24.70 (-2.29, -8.48%)
Weekly Expected Move ±10.7%
$18
$21
$24
$26
$29
Credit Risk of going bust: lower than 55% of companies Debt: 2.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.08 (down 99.7%), Neurogene Inc. would be worth roughly what it owes.
Total debt $8.3M against a stock market value of $372.0M.
Distance to default 5.60 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.2M (short-term plus half of long-term), stock volatility 76.8%; Altman Z'' 5.31. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.08 (down 99.7%), Neurogene Inc. would be worth roughly what it owes.
Total debt $8.3M against a stock market value of $372.0M.
Distance to default 5.60 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.2M (short-term plus half of long-term), stock volatility 76.8%; Altman Z'' 5.31. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$372.0M
52W Range15.93-43.66
Volume123,200
Avg Volume283,073
Beta2.09
Dividend—
Analyst Ratings
Company Info
CEORachel L. McMinn
Employees131
SectorHealthcare
IndustryBiotechnology
IPO Date2014-03-07
Websiteneurogene.com
535 W 24th Street
New York City, NY 10011
US
New York City, NY 10011
US
(877) 237-5020
About Neurogene Inc.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Latest News
Neurogene Inc. (NASDAQ:NGNE) Stock Has Average Target Price of $80.29 According to Brokerages
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
Neurogene (NASDAQ:NGNE) Sees Large Volume Increase – Should You Buy?
Neurogene is a new Overweight at J.P. Morgan on Rett syndrome therapy
Neurogene Inc. (NASDAQ:NGNE) Stock Has Consensus Price Target of $83.67
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| McMinn Rachel | M-Exempt | 756 | $25.32 | 2026-09-22 |
| McMinn Rachel | M-Exempt | 756 | $25.32 | 2026-09-22 |
| Cvijic Christine Mik | S-Sale | 4,200 | $36.13 | 2026-07-07 |
| Cvijic Christine Mik | S-Sale | 600 | $36.02 | 2026-07-06 |
| Cvijic Christine Mik | S-Sale | 2,531 | $34.58 | 2026-07-02 |